$PTLA Headlines Results from study of Portola's factor Xa

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$PTLA Headlines

Results from study of Portola's factor Xa inhibitor antidote presented at ASH 11:27 a.m. Dec. 9, 2013 - Seeking Alpha
Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO 10:05 a.m. Dec. 9, 2013 - benzinga.com
ASH Conference: 3 Companies To Watch 10:53 a.m. Dec. 8, 2013 - Seeking Alpha
A Chart You Should See: Biotech IPO Class of 2013 Is Lagging 9:42 a.m. Nov. 26, 2013 - TheStreet.com
Health-Care Stocks: Where to Find Value 6:08 a.m. Nov. 12, 2013 - Barrons.com
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 7:03 a.m. Nov. 11, 2013 - benzinga.com
10-Q: PORTOLA PHARMACEUTICALS INC 5:26 p.m. Nov. 6, 2013 - Edgar Online - (EDG = 10Q, 10K)
Portola Pharmaceuticals Inc's CEO Discusses Q3 2013 Results - Earnings Call Transcript 12:23 a.m. Nov. 6, 2013 - Seeking Alpha
Portola Pharmaceuticals: A Biotech Company With Plenty Of Room To Grow 12:18 p.m. Oct. 30, 2013 - Seeking Alpha
Portola Strengthens On Hopes For Cardiovascular Franchise 1:46 p.m. Oct. 21, 2013 - Seeking Alpha
Portola Prices Public Offering - Analyst Blog 4:30 p.m. Oct. 18, 2013 - Zacks.com
Data on Portola's Andexanet Alfa - Analyst Blog 4:30 p.m. Oct. 15, 2013 - Zacks.com
Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445 3:06 p.m. Oct. 14, 2013 - benzinga.com
Update on Portola's Pipeline - Analyst Blog 12:40 p.m. Oct. 14, 2013 - Zacks.com
Portola Pharmaceuticals to Present Preclinical Data on Andexanet Alfa 6:05 a.m. Aug. 29, 2013 - benzinga.com
Portola Pharmaceuticals' CEO Discusses 2Q 2013 Results - Earnings Call Transcript 1:44 p.m. Aug. 16, 2013 - Seeking Alpha
Encouraging Data on Portola's PRT4445 - Analyst Blog 4:20 p.m. July 9, 2013 - Zacks.com
Bayer Announces Positive Phase I Data - Analyst Blog 4:00 p.m. July 8, 2013 - Zacks.com
Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R) 5:32 a.m. July 2, 2013 - benzinga.com
Portola Pharmaceuticals: Developing The Novel Therapies In Blood Clot Formation Disorders 3:01 p.m. July 1, 2013 - Seeking Alpha


Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban) With Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Reversal Agent 11:00 a.m. Dec. 9, 2013 - GlobeNewswire
District Court Ruling, Cash Tender Offers, Celebration Events, Conference Presentations, and Repurchase Programs - Research Report on AstraZeneca, Salix, Health Net, Volcano and Portola 8:00 a.m. Dec. 9, 2013 - PR Newswire
Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Society of Hematology (ASH) Annual Meeting 8:00 a.m. Dec. 3, 2013 - GlobeNewswire
Proposed M&A's, Conference Schedules, Health Awareness Programs, Prestigious Recognitions and FDA Designations - Research Report on Health Management, Acadia, Health Net, NuVasive and Portola 8:00 a.m. Nov. 29, 2013 - PR Newswire
Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Antidote 8:01 a.m. Nov. 25, 2013 - GlobeNewswire
Disaster Relief Contributions, New Medical Trials, Clinical Results and Employee Incentives - Research Report on UnitedHealth Group, ACADIA, USANA, Portola and Horizon Pharma 8:00 a.m. Nov. 21, 2013 - PR Newswire
Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA, Repligen, and Portola 8:11 a.m. Nov. 13, 2013 - PR Newswire
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 8:01 a.m. Nov. 11, 2013 - GlobeNewswire
Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update 4:00 p.m. Nov. 5, 2013 - GlobeNewswire
Portola Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013 7:00 a.m. Oct. 31, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers 3:00 p.m. Oct. 24, 2013 - GlobeNewswire
Divestiture, Clinical Study Updates, New Drug Application, and Quarterly Report - Research Report on Geron, NPS, Portola, MannKind, and Exact Sciences 7:00 a.m. Oct. 21, 2013 - PR Newswire
PACT, EBAY, AMRN and PTLA added to NASDAQ Active Stock Watch List at GSR 9:10 a.m. Oct. 17, 2013 - ACCESSWIRE
Portola Announces Pricing of Public Offering of Common Stock 7:33 a.m. Oct. 17, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Proposed Offering of Common Stock 5:56 a.m. Oct. 16, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company 4:05 p.m. Oct. 15, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis(R) 4:05 p.m. Oct. 14, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of PRT2070 7:01 a.m. Oct. 9, 2013 - GlobeNewswire
Vital Therapies, Inc. Expands Board of Directors 5:01 a.m. Sept. 20, 2013 - Marketwire
Portola Pharmaceuticals Announces Participation at Upcoming Investor Conferences 7:01 a.m. Sept. 5, 2013 - GlobeNewswire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 10

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Microbot Medical Secures $13 Million in Recent Offering

Updated Category News Views 92

Microbot Medical Makes Strategic Move with $13 Million Offering Microbot Medical Inc. (NASDAQ: MBOT) has recently taken an important step to elevate its operations by entering into definitive agreements to sell 6,103,289 shares of its common stock at a price of $2.13 per share. This registered direct offering, priced at-the-market under Nasdaq rules, underscores the...

Continue Reading
Evolv Technologies Faces Class Action Lawsuit: Know Your Rights

Updated Category News Views 651

Understanding the Evolv Technologies Holdings Class Action Recent developments have raised significant concerns among shareholders of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV). A class action lawsuit is currently in progress, prompting investors to scrutinize the implications of false statements made by the company. The allegations revolve around misleading...

Continue Reading
Rhino Rescue Unveils Innovative First Aid Kits for Adventurers

Updated Category News Views 117

Rhino Rescue Launches Innovative Products for Outdoor Safety Rhino Rescue has made a remarkable stride in enhancing outdoor safety with its new lineup of first aid kits targeted towards adventurers and everyday users alike. The release of the Rhino Rescue Mini First Aid Kit, along with home and camping-specific options, marks an exciting development in the company’s...

Continue Reading
RUSH's 2026 Tour: Celebrating Legacy and New Beginnings

Updated Category News Views 258

RUSH's 2026 Tour: A Celebration of Music and Legacy Geddy Lee and Alex Lifeson are set to celebrate over 50 years of RUSH's musical journey as they announce a special headline tour for 2026, named the Fifty Something Tour. This tour not only commemorates the incredible music and legacy of RUSH, but also pays tribute to their late drummer and lyricist Neil Peart, whose...

Continue Reading
BioSyent Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 132

BioSyent Inc. Announces Quarterly Dividend for Shareholders MISSISSAUGA, Ontario — BioSyent Inc. (TSX Venture: RX) is thrilled to communicate that its Board of Directors has approved a quarterly dividend of $0.05 per common share. This dividend will be paid in Canadian Dollars on a specified date to shareholders who are on record, enhancing the company's ongoing...

Continue Reading